Holen Sie sich die Stockscreener-App
4.04
2.18%
-0.09
Handel nachbörslich:
4.10
0.06
+1.49%
Schlusskurs vom Vortag:
$4.13
Offen:
$4.29
24-Stunden-Volumen:
115.77K
Relative Volume:
0.69
Marktkapitalisierung:
$21.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.21M
KGV:
-0.1239
EPS:
-32.6
Netto-Cashflow:
$-16.86M
1W Leistung:
-3.12%
1M Leistung:
-10.62%
6M Leistung:
-10.42%
1J Leistung:
-15.83%
1-Tages-Spanne:
$3.91
$4.3072
1-Wochen-Bereich:
$3.50
$4.31
52-Wochen-Spanne:
$3.02
$20.83
Cingulate Inc Stock (CING) Company Profile
Firmenname
Cingulate Inc
Sektor
Branche
Telefon
(913) 942-2300
Adresse
1901 W. 47TH PLACE, KANSAS CITY
Vergleichen Sie CING mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.04 | 21.25M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | ROTH MKM | Buy |
| 2023-12-22 | Herabstufung | Laidlaw | Buy → Hold |
Cingulate Inc Aktie (CING) Neueste Nachrichten
KC company puts CEO on leave days after second domestic battery arrest - yahoo.com
Cingulate puts CEO on leave days after second domestic battery arrest - The Business Journals
Cingulate Inc. Delays Quarterly Report Filing - TipRanks
Cingulate places CEO Shane Schaffer on leave, appoints interim leadership By Investing.com - Investing.com Nigeria
Cingulate Places CEO Shane Schaffer on Administrative Leave - MarketScreener
Cingulate Inc CEO Shane Schaffer on Administrative Leave - TipRanks
Cingulate places CEO on leave, appoints interim leadership - Investing.com
Cingulate Provides Management Team Update - GlobeNewswire
Leadership Change: Cingulate Appoints CFO Jennifer Callahan as Interim CEO Amid ADHD Drug FDA Review - Stock Titan
KC-area public company CEO faces felony charge for choking his girlfriend - FOX4KC.com
Investors Hope for Bounce in Cingulate Inc. Equity Warrant After SelloffFree Access to Community - beatles.ru
Cingulate terminates COO one day after submitting drug for FDA approval - The Business Journals
Analyzing drawdowns of Cingulate Inc. with statistical toolsTrade Ideas Based on Fundamental Metrics - Newser
Why Cingulate Inc. Equity Warrant is moving todayFree Chart Driven High Reward Trading Setup - Newser
Identifying reversal signals in Cingulate Inc. Equity WarrantAI Powered Buy Point Forecast Planner - Newser
How to read the order book for Cingulate Inc.Free Trade Scanner With Buy Zone Alerts - Newser
Smart tools for monitoring Cingulate Inc.’s price actionFree Short Term Setup With Predictive Chart - Newser
Does Cingulate Inc. Equity Warrant show high probability of reboundFree Triple Return Setup with Risk Control - Newser
Is Cingulate Inc. Equity Warrant reversing from oversold territoryReal Time Stock Movement and Alerts - Newser
Understanding Cingulate Inc.’s price movementFree Pattern Alert With ROI Driven Strategy - Newser
What technical models suggest about Cingulate Inc.’s comebackTechnical Insight Guide for Safer Trades - Newser
Using R and stats models for Cingulate Inc. Equity Warrant forecastingSwing Reversal Forecast Based on Patterns - Newser
Using data filters to optimize entry into Cingulate Inc. Equity WarrantEntry Timing with Downside Risk Analysis - Newser
Cingulate CEO tells Roth COO departure has no meaningful impact on CTx-1301 - TipRanks
What momentum shifts mean for Cingulate Inc.Swing Trade Timing with Daily Forecast - Newser
Cingulate Inc.’s Strategic Partnerships and NDA Submission Drive Buy Rating - TipRanks
Cingulate submits CTx-1301 NDA to FDA - TipRanks
Cingulate Inc Submits NDA for ADHD Treatment - TipRanks
Cingulate submits NDA for ADHD treatment to FDA By Investing.com - Investing.com Canada
Cingulate submits NDA for ADHD treatment to FDA - Investing.com
Cingulate Submits New Drug Application for ADHD Asset CTx-1301 to FDA - AInvest
Cingulate Submits NDA for CTx-1301, ADHD Treatment with Extended-Release Tablet - AInvest
Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301 - GlobeNewswire
META Gets Huge Upgrades: How High Analysts Think Shares Could Go - The Globe and Mail
How many analysts rate Cingulate Inc. Equity Warrant as a “Buy”Unlock exclusive stock market insights - Jammu Links News
Cingulate Inc. Stock Analysis and ForecastDiscover breakthrough investment opportunities - Jammu Links News
What is Cingulate Inc. company’s growth strategyRapid market gains - Jammu Links News
How does Cingulate Inc. Equity Warrant generate profit in a changing economyMaximize returns with smart investment plans - Jammu Links News
How many analysts rate Cingulate Inc. as a “Buy”Maximize portfolio growth with expert advice - Jammu Links News
How strong is Cingulate Inc. company’s balance sheetMaximize portfolio growth with strategic plans - Jammu Links News
When is Cingulate Inc. stock expected to show significant growthMarket-leading capital gains - Jammu Links News
What drives Cingulate Inc. stock priceRapid wealth multiplication - Jammu Links News
Why is Cingulate Inc. stock attracting strong analyst attentionFree Stock Index Interpretation - Jammu Links News
What analysts say about Cingulate Inc. Equity Warrant stockInvest confidently with real-time market updates - Jammu Links News
What are the latest earnings results for Cingulate Inc. Equity WarrantBuild a diversified portfolio for steady profits - Jammu Links News
Is it the right time to buy Cingulate Inc. stockUnlock powerful market trend analysis - Jammu Links News
What institutional investors are buying Cingulate Inc. Equity Warrant stockFree Investment Timing Strategies - Jammu Links News
What is Cingulate Inc. Equity Warrant company’s growth strategyExplosive returns - Jammu Links News
What are the technical indicators suggesting about Cingulate Inc.Uncover the best stocks for explosive growth - Jammu Links News
What is the dividend policy of Cingulate Inc. stockBuild a strong portfolio for growth and safety - Jammu Links News
What makes Cingulate Inc. stock price move sharplyUnlock powerful insights from market experts - Jammu Links News
Finanzdaten der Cingulate Inc-Aktie (CING)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):